Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients.

ABSTRACT:

Background

Sickle cell disease (SCD) is an inherited blood disorder characterized by chronic hemolysis, inflammation, and vaso-occlusive crises (VOC), leading to multiple complications and reduced life expectancy in affected individuals. Limited effective treatment options are currently available; however, recent genomic findings from underrepresented populations (Saudi Arabians) have offered new hope for predicting molecularly guided treatments. This study aimed to identify approved drugs suitable for repurposing based on their interactions with SCD-associated genetic variants and to discover novel druggable targets within genetic pathways linked to disease severity by utilizing genome-wide association study (GWAS) data from Saudi SCD patients.

Methods

Bioinformatic pipelin

SUBMITTER: Alghubayshi A 

PROVIDER: S-EPMC12705626 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature